| Literature DB >> 24906621 |
Eva Pastille1, Katrin Bardini1, Diana Fleissner1, Alexandra Adamczyk1, Annika Frede1, Munisch Wadwa1, Dorthe von Smolinski2, Stefan Kasper3, Tim Sparwasser4, Achim D Gruber2, Martin Schuler5, Shimon Sakaguchi6, Axel Roers7, Werner Müller8, Wiebke Hansen1, Jan Buer1, Astrid M Westendorf9.
Abstract
Regulatory T cells (Treg) are supportive to cancer development in most tissues, but their role in colitis-associated colon cancer (CAC) remains unclear. In this study, we investigated the role of CD4(+)Foxp3(+) Treg in a mouse model of CAC and in patients with colon cancer. These Treg were increased strongly in number in a mouse model of CAC and in the peripheral blood of patients with colon cancer, exhibiting an activated phenotype as defined by elevated expression of GARP, CD103, CTLA-4, and IL10, along with an increased suppressive effect on the proliferation and Th1 cytokine expression of CD4(+)CD25(-) responder T cells ex vivo. Transient ablation of CD4(+)Foxp3(+) Treg during tumor development in the CAC model suppressed tumor outgrowth and distribution, accompanied by an increased number of CD8(+)IFNγ/granzyme B-producing effector T cells. Conversely, inactivation of IL10 in Treg did not elevate the antitumor response but instead further boosted tumor development. Our results establish a tumor-promoting function for Treg during CAC formation, but they also suggest that a selective, transient ablation of Treg can evoke antitumor responses, with implications for immunotherapeutic interventions in patients with CAC. ©2014 American Association for Cancer Research.Entities:
Mesh:
Year: 2014 PMID: 24906621 DOI: 10.1158/0008-5472.CAN-13-3065
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701